Breaking News, Collaborations & Alliances

SIGA Technologies Enters Collaboration with KaliVir Immunotherapeutics

Will make TPOXX available for use with KaliVir’s proprietary oncolytic vaccinia immunotherapy platform.

Author Image

By: Charlie Sternberg

Associate Editor

SIGA Technologies Inc., a commercial-stage pharmaceutical company focused on the health security market, has announced a collaboration with KaliVir Immunotherapeutics to make TPOXX (tecovirimat) available for use with KaliVir’s proprietary oncolytic vaccinia immunotherapy platform.   This novel oncolytic platform includes multiple proprietary genetic modifications that can be combined to generate a unique oncolytic virus that has been optimized for systemic delivery and anti-tumor immune stimu...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters